Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrell R Fisher

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Scientific Reports|October 27, 2022
Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging systemRobin Peter, Brenda M Sandmaier, Michael P Dion, et al.
Blood|March 9, 2013
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia modelJohnnie J Orozco, Tom Bäck, Aimee Kenoyer, et al.
Plos One|December 3, 2014
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia modelJohnnie J Orozco, Ethan R Balkin, Ted A Gooley, et al.
Blood Advances|October 14, 2021
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphomaVictor A Chow, Ryan D Cassaday, Theodore A Gooley, et al.
Blood|September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndromeJohn M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica|October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasiaPhuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term SurvivorsJohnnie J Orozco, Phuong T Vo, Ted A Gooley, et al.
Cancer Research|June 2, 2017
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell LymphomasShyril O'Steen, Damian J Green, Ajay K Gopal, et al.
Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Scientific Reports|October 27, 2022
Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging systemRobin Peter, Brenda M Sandmaier, Michael P Dion, et al.
Blood|March 9, 2013
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia modelJohnnie J Orozco, Tom Bäck, Aimee Kenoyer, et al.
Plos One|December 3, 2014
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia modelJohnnie J Orozco, Ethan R Balkin, Ted A Gooley, et al.
Blood Advances|October 14, 2021
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphomaVictor A Chow, Ryan D Cassaday, Theodore A Gooley, et al.
Blood|September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndromeJohn M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica|October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasiaPhuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term SurvivorsJohnnie J Orozco, Phuong T Vo, Ted A Gooley, et al.
Cancer Research|June 2, 2017
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell LymphomasShyril O'Steen, Damian J Green, Ajay K Gopal, et al.
Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
Pageof 9